Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- PMDA Announces Measures to Improve Its Services
October 24, 2005
- Control Medical Spending Based on Growth in "Aging-adjusted GDP": Council Experts
October 24, 2005
- UTOBRAIN SEMINAR
October 24, 2005
- Korosho to Include MOF's Viewpoints in Its Healthcare Reform Plan Proposal for FY2006
October 24, 2005
- Pfizer Establishes Website on Research Tools in Collaboration with US NIH
October 24, 2005
- Aripiprazole Recommended for Approval
October 24, 2005
- Are Placebo-controlled Studies Essential for Antidepressants?: Dr Sato of TRC
October 24, 2005
- REGULATORY NEWS IN BRIEF
October 24, 2005
- JHSF Seminars on Drug Discovery Research
October 24, 2005
- Drug Distribution Council Resumes Discussions
October 24, 2005
- JAPIC Seminar on Optimal Healthcare for Patients
October 24, 2005
- Eisai, TorreyPines Announce New Research Program for Alzheimer's Disease
October 24, 2005
- R&D NEWS IN BRIEF
October 24, 2005
- Nippon Kayaku to Make Full Entry into Generic Anticancer Drugs
October 24, 2005
- Correct Knowledge of MS Is Essential: Nihon Schering
October 24, 2005
- BUSINESS NEWS IN BRIEF
October 24, 2005
- DDW-Japan 2005 Held in Kobe
October 24, 2005
- Dr Derek Gilroy Wins Bayer HC's 10th Int'l Aspirin Award
October 24, 2005
- SEMINAR
October 24, 2005
- PMDA to Establish Approval Standards for More OTC Drugs
October 24, 2005
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…